Journal article
The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis
Abstract
BACKGROUND: Anthracycline-taxane is the standard chemotherapy strategy for treating high-risk early breast cancer despite the potentially life-threatening adverse events caused by anthracyclines. Commonly, the combination of docetaxel and cyclophosphamide (TC) is considered an alternative option. However, the efficacy of TC compared to anthracycline-taxane chemotherapy is unclear. This study compares disease-free survival (DFS), overall …
Authors
de Mello Morais Mata DG; Rush M-B; Smith-Uffen M; Younus J; Lohmann AE; Trudeau M; Morgan RL
Journal
Current Oncology, Vol. 31, No. 8, pp. 4486–4506
Publisher
MDPI
DOI
10.3390/curroncol31080335
ISSN
1198-0052